SEOUL - Hanmi Pharmaceutical Co. Ltd. has inked a licensing out agreement with Janssen Pharmaceutical Cos. for the development and commercialization of its diabetes and obesity therapy HM12525A, a long-acting GLP/GCG analog.
Following a string of major licensing out deals with multinationals this year, the agreement will bring further international recognition of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?